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Human papillomavirus (HPV) infection is the most common sexually transmitted infection;
persistent infection with high-risk types of HPV present a major risk factor for the initia-
tion and progression of a variety of human carcinomas including cervical, colorectal, head,
and neck (HN) as well as breast carcinomas. A huge number of studies investigated and
reported the incidence of high-risk HPVs in these cancers worldwide particularly in the
developed countries; therefore, two HPV prophylactic vaccines against the two most fre-
quent high-risk HPV types (16 and 18) have been developed and used worldwide. However,
there are very limited studies about the prevalence of HPVs in the developing countries
especially in Africa and some states of the Middle East. In this mini review, we outline the
presence of high-risk HPVs in human cervical, colorectal, HN as well as breast cancers in
the Syrian population, which was recently explored for the first time by a Canadian/Syrian
group.
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INTRODUCTION
Human papillomaviruses (HPVs) are considered among the major
viruses associated with human cancers especially cervical carci-
nomas (1). HPVs are the most common sexually transmitted
infections worldwide, with the majority of individuals who engage
in sexual activity becoming infected at some point in their lifetime;
HPVs are small, double-stranded DNA viruses that generally infect
cutaneous and mucosal epithelial tissues of the anogenital tract
(1, 2). To date, over 120 different viral types have been identified;
HPVs are classified as either high risk or low risk, with high-risk
types being associated with cancer formation. Infections with low-
risk types are generally self-limiting and do not lead to malignancy
(3–5). However, infections with high-risk HPVs (type 16, 18, 31,
33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 73, 82, and 83) are asso-
ciated with the development of cervical cancers where more than
96% of these cancers are positive for high-risk HPVs worldwide
(1, 6). Moreover, accumulating evidence suggests that persistent
infection with those viruses is necessary for cervical precursors
to evolve into invasive carcinomas (1, 7, 8). High-risk HPVs are
important risk factors for other human cancers as well, such as
head and neck (HN) and colorectal carcinomas; as roughly 30 and
80% of these cancers are positive for high-risk HPVs, respectively
(9–11). Moreover, it was observed that the presence of high-risk
HPVs serve as a prognostic factor in early-stage cervical, HN, and
colorectal cancers, and could be associated with vascular inva-
sion, lymph node metastases, and tumor size (12–16). In addition,
numerous recent studies revealed that high-risk HPVs are present
in human breast cancers worldwide (17–21); controversially few
studies did not confirm this statement (22–24).
Earlier studies revealed that the prevalence of HPV infections
in human cancers is related to specific geographic locations world-
wide (3, 25). On the other hand, it is important to mention
that the majority of studies on the incidence of HPVs and their
role in human cancers were carried out in countries with high
to intermediate economic rank (25); however, there are a small
number of investigations regarding the presence and incidence
of these viruses in the developing countries including Africa and
some states of the Middle East (ME) (3, 26). Thus in this paper,
we reviewed cancer cases identified by the Pathology Depart-
ment of the main teaching hospital of the Faculty of Medicine
of Aleppo University, which is one of the major universities in
Syria, and investigated the presence and distribution of high-risk
HPVs in cervical, HN, colorectal, and breast cancers in the Syrian
population.
HIGH-RISK HPVs IN CERVICAL CANCER
It is well established that high-risk HPVs are important risk factors
for human cervical cancers; as roughly 96% of these cancers are
positive for high-risk HPVs, and the most frequent HPV types are
16 and 18 worldwide (6, 7); therefore, two HPV vaccines against
these two types of viruses have been generated and spread world-
wide (Gardasil®) and (Cervarix®). Meanwhile, it is important to
emphasize that there are few studies regarding the presence and
distribution of high-risk HPVs in human cervical cancers in the
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majority of the developing countries (26, 27), which is an impor-
tant initiator to HPV vaccines introduction in these countries.
Accordingly, there is only one study about the incidence of high-
risk HPVs in cervical cancer on the Syrian population, which was
recently performed in collaboration between a Canadian group of
McGill University and their colleagues of Aleppo University (28).
In this study, the authors investigated the presence of high-risk
HPV types 16, 18, 31, 33 35, 45, 51, 52, and 58 in a cohort of 44
cervical cancer samples from Syrian women, with an average age
of 57 years, by polymerase chain reaction (PCR) analysis, using
specific primers for E7 gene, and immunohistochemistry (IHC)
methodology (Table 1). This study revealed that 38 (95.45%) of
the 42 samples are HPV positive and all of these positive speci-
mens are co-infected with more than one HPV type; moreover,
HPV types 33, 16, 18, 45, and 52 are the predominant viruses of
the high-risk HPVs family in these cervical cancer tissues. On the
other hand, this investigation reported that the presence of high-
risk HPVs is correlated with Id-1 gene over-expression in 95.23%
of human cervical cancers, which are invasive carcinomas in the
majority of cases. Accordingly, it was displayed that Id-1, a member
of the helix–loop–helix transcription factor family, is expressed in
the majority of invasive cervical carcinomas (29). More signifi-
cantly, this study revealed that the prevalence of high-risk HPV in
carcinomas of the cervix in Syria is approximately similar to those
reported in other countries in the ME and North Africa, particu-
larly in Turkey (30–53). Nevertheless, we believe that future studies
on a larger number of samples, from several provinces of Syria are
needed to confirm the incidence of HPVs in cervical cancer in this
country.
HIGH-RISK HPVs IN HEAD AND NECK CANCERS
Cancers of the HN (upper aerodigestive tract) include neoplasias
of the oral cavity, the pharynx (naso-, oro-, and hypopharynx),
the larynx, and the paranasal sinuses (54). Head and neck squa-
mous cell carcinomas (HNSCCs) are the predominant tumors
of the HN comprising more than 95% of all HN cancers (55,
56). Currently it is assumed that high-risk HPVs infections are
important factors in the development of HNSCCs, as approxi-
mately 30% of these cancers are positive for high-risk HPVs (9,
10, 57). As we mentioned above, the presence and allocation of
these viruses in human cancers, including HNSCCs, are related
to specific geographic locations worldwide (3, 10, 25). However,
the presence of HPVs in HN cancers in the developing coun-
tries, including Syria, is limited to insufficient number of studies.
For instance in Syria, the same Canadian/Syrian group recently
investigated the presence of high-risk HPVs in a cohort of 80 HN
cancer tissue samples (7 females and 73 males with a median age
of 54.5 years) from the Syrian population using IHC analysis and
tissue microarray methodology. All the samples were squamous
cell carcinomas (57 larynx, 21 lips, and 1 nasopharynx). The data
of this study revealed that 43% of these cancers are positives for
high-risk HPVs. Genotyping of high-risk HPVs is presently under
investigation by the same group (Table 1); however, preliminary
data from this study reveal that HPV types 16, 18, 31, 33, and 35
are frequent in HN cancers in Syria (Ghabreau et al., in prepara-
tion). On the other hand, authors of this investigation explored
the association between the presence of high-risk HPVs and p53
expression in this population; their data did not show an evident
correlation between these viruses and p53 in their samples.
Accordingly, the incidence of high-risk HPVs in HN cancers
in the Syrian population is comparable to the prevalence of these
viruses in Turkey. It is worth mentioning that Turkey is one of the
neighboring countries of Syria where HPV prevalence studies have
been conducted in HN; specifically, there have been four studies
exploring the presence and distribution of HPVs in HN cancers
using PCR methodology; these studies showed that the presence
of high-risk HPVs varies from 14 to 47.6%, and the most frequent
HPVs in the Turkish population are HPV types 16, 18, 31, and
33 (58–60). However, there have not been any similar studies to
date in the other neighboring countries such as Iraq, Lebanon,
and Jordan with the exception of one study conducted in Israel. In
this investigation, the authors examined the presence of only HPV
type 16 in 23 oral and oropharynx carcinoma cases by PCR; their
data revealed that four samples (17.3%) are positive for this type
of high-risk HPV (61).
In conclusion, it is evident that high-risk HPVs are present in
HN cancers in the Syrian population and their presence is compa-
rable to HN cancers in Turkey. However, it is important to highlight
that the Canadian/Syrian study was limited to an insignificant
number of cases located in a single region of Syria; therefore, it
is essential to perform other studies to confirm the incidence and
types of these viruses in the Syrian population.
Table 1 | List of studies regarding the incidence of high-risk HPVs in human cervical, head and neck, colorectal, and breast cancer in the Syrian
population.
Anatomical cancer site Number of cases Assay HPVs positive % Most frequent HPV types Reference
Cervical 44 PCR/TMa 95.45 33, 16, 18, 45, and 52 Darnel et al. (28)
Head and neck 80 PCR/TM 43 16, 18, 31, 33, and 35b In preparation
Colorectal 78 PCR/TM 53.84 16, 33, 18, 35, and 31 Ghabreau et al. (69)
Breast 113 PCR/TM 61.06 33, 35, 16, 81, and 51 Akil et al. (75)
aTissue microarray.
bThese data are preliminary.
All these studies were done on paraffin-embedded tissue samples that were collected from the major teaching.
Hospital of the Faculty of Medicine of Aleppo University.
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HIGH-RISK HPVs IN COLORECTAL CANCER
Colorectal cancer is the third most common type of cancer, with
approximately 1.3 million new cases diagnosed annually world-
wide, accounting for about 9.7% of all cancer cases (WHO).
Evidence from recent studies suggests that environmental con-
ditions and lifestyle in addition to sequential genetic changes and
possibly viral components are major risk factors for colorectal
cancer (62). Therefore, it was recently pointed-out that high-risk
HPVs have carcinogenic effects at several anatomical sites in both
women and men such as colorectal (16, 63, 64). These studies
showed that high-risk HPVs are present in approximately 80%
of colorectal cancers, especially in their invasive form worldwide;
however, a small number of studies, including ones from ME (65),
did not confirm this fact. In this context, it is important to high-
light that there is a few investigations about the presence of HPVs
in colorectal cancers in the developing countries including one
study from Syria, which was performed by the Canadian/Syrian
group (Table 1). This group has investigated the presence of high-
risk HPVs and their association with Fascin, Id-1, and P-cadherin
genes, which are major regulators of cell invasion and metasta-
sis (66–68), in human colorectal cancers in the Syrian population
(69). In this study, the authors used PCR and tissue microarray
analysis to explore the presence of HPV and E6 expression, respec-
tively, in a cohort of 78 cancer tissues (41 females and 37 males
with a median age of 49 years). This study revealed that high-risk
HPVs are present in 42 samples (53.84%); the most frequent high-
risk HPV types in the Syrian population are 16, 33, 18, 35, and 31,
respectively. Furthermore, the expression of E6 onco-protein of
high-risk HPVs was found to be associated with Fascin, Id-1, and
P-cadherin expression in the majority of cancer tissue samples.
Data of this investigation showed, for the first time, that high-risk
HPVs are present in human colorectal cancers in the Syrian popu-
lation and their presence is associated with invasive and metastatic
phenotype (69). On the other hand, it is important to indicate that
the presence of HPVs in colorectal cancers in the ME is limited
only to four studies one from Israel (65) and three from Turkey
(70–72). The first study, from Turkey, found that high-risk HPVs
are present in 46 of 56 colorectal cancer tissues, which represent
82.14% HPV-positive cases (70). This study revealed that the most
frequent HPVs in colorectal cancers in Turkey are HPV types 18
and 33. The second study was conducted on a cohort of 43 colorec-
tal cancer tissues, and reported that 55.8% of these cancer cases are
positive for high-risk HPVs especially types 18 and 33 (71). How-
ever, the third study was unable to detect the presence of HPVs
in 106 colorectal cancer samples (72). These studies used PCR
approach to detect the presence of HPVs in their samples. In con-
clusion, the Syrian and Turkish studies suggest that HPV types 18
and 33 are common in colorectal cancers in Syria as well as Turkey;
in this context, it is important to mention that the Syrian study was
conducted in Aleppo, which is close to the Turkish border. How-
ever, we believe that more investigations in several areas of Syria
are necessary to elicit a clear image of the presence and distribution
of high-risk HPVs in colorectal cancers in the Syrian population.
HIGH-RISK HPVs IN BREAST CANCER
Breast cancer is the most common malignancy in women world-
wide; and metastatic breast disease is a major cause of morbidity
and mortality in breast cancer patients. Several earlier studies
reported that high-risk HPVs are present in approximately 50%
of human breast cancers worldwide (17–21); controversially a few
studies were unable to detect the presence of HPVs in breast cancer
as well as normal mammary tissues (22–24). On the other hand,
it was pointed-out that the presence of high-risk HPVs especially
types 16 and 18, in human breast cancer, is correlated with inva-
sive carcinomas phenotype (19, 21, 73). More significantly, it was
demonstrated that E6/E7 onco-proteins of HPV type 16 covert
non-invasive and non-metastatic breast cancer cells to invasive
and metastatic form, in vitro and in nude mice, respectively (3,
74). Regarding the presence of high-risk HPVs in breast cancer in
Syrian women, the Canadian/Syrian group investigated the inci-
dence of HPV types 16, 18, 31, 33, and 35 in a cohort of 113
breast cancer tissue samples (with a median age of 52 years) by
PCR analysis using specific primers for their E6 and/or E7 genes
and tissue microarray approach (75). This study revealed that 69
(61.06%) of the 113 samples are HPV positive and 24 (34.78%)
are co-infected with more than one HPV type; in addition, HPV
types 16, 18, and 31 are present in 10, 11, and 8 cancer tissues,
respectively. In contrast, 63 and 42 cancer tissues were positive for
HPV types 33 and 35, respectively. Therefore, the authors con-
cluded that the most frequent high-risk HPVs in breast cancer in
Syrian women are HPV types 33 and 35. On the other hand, this
investigation reported that the presence of high-risk HPVs is cor-
related with Id-1 gene over-expression in human breast cancers,
as it was revealed in human cervical cancer (28).
The Canadian/Syrian group data of HPVs in breast cancers
(Table 1) are similar to a Turkish study, which was performed in
50 breast cancers and normal mammary tissues using PCR analy-
sis (76). In this study, authors reported that 74% of malignant
breast tissues are positive for HPVs; and the most common high-
risk HPVs in the Turkish women are types 33 and 35. Herein,
it is important to mention that there is another study from ME
(from Tunisia) that did not confirm the presence of HPVs in breast
cancer (24). In conclusion, we believe that HPVs are present in
human breast cancer in the ME region including Syria. However,
more investigations are necessary to confirm their present and
distribution of HPVs in the Syrian population.
CONCLUSION AND FUTURE PERSPECTIVE
In this paper, we have reviewed the incidence of high-risk HPV
infections and their associated cancers including cervical, HN,
colorectal, and breast in the Syrian population. Although data
of HPVs and their related cancers worldwide are evident, the inci-
dence of HPVs in the Syrian population needs more investigations
to be confirmed. The presence of these viruses in Syria is limited to
one study from the same group for each anatomical site; in addi-
tion, these studies are conducted in one region of Syria, which is
near the Turkish border. It is important to highlight that presently
available HPVs vaccines can protect only against HPV types 16 and
18 and their associated cancers, which are the most frequent types
in western countries; so far this does not seem to be the case in
the Syrian population based on the Canadian/Syrian group studies
[(77) and Table 1]. In addition and based on the cost and efficacy
of the two available vaccines as well as the availability of the second
generation of HPV vaccine, which will be against high-risk types
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16, 18, 31, 33, 45, 52, and 58, in addition to two low-risk types, 6
and 11 (78), we believe that the populations of developing coun-
tries including Syria should wait for the new generation of the
HPV’s vaccine. Meanwhile, we incite our colleagues in develop-
ing countries including Syria to reassess the incidence of high-risk
HPVs in their respective populations, which is an important step
to eliminate these viruses and associated cancers worldwide.
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